Medicine and Dentistry
Patient
52%
Patient with Inflammatory Bowel Disease
51%
Crohn's Disease
39%
Ulcerative Colitis
31%
Hazard Ratio
26%
Incidence
25%
Age
25%
Inpatient
23%
Diagnosis
23%
Cohort Analysis
19%
Association
19%
Tumor Necrosis Factor
18%
Combination Therapy
18%
Patient with Ulcerative Colitis
17%
Therapeutic Procedure
17%
Inflammatory Bowel Disease
16%
Patient with Crohn's Disease
16%
Person
15%
Odds Ratio
15%
Mercaptopurine
15%
Maturity Onset Diabetes of the Young
14%
Adult
13%
Diseases
12%
Meta-Analysis
11%
Childhood
11%
Body Mass Index
11%
Sex
10%
Life
10%
Family
10%
Health
9%
Mesalazine
9%
Surgery
9%
Obesity
8%
Necrosis
8%
Follow up
8%
Infection
8%
Colorectal Cancer
8%
Lesion
8%
Development
7%
Surveillance
7%
Malignant Neoplasm
7%
Proportional Hazards Model
7%
Systematic Review
6%
Standardized Incidence Ratio
6%
COVID-19
6%
Infliximab
6%
Woman
6%
Man
6%
Antibiotics
6%
Antibiotics
6%
Nursing and Health Professions
Inflammatory Bowel Disease
58%
Patient
27%
Inpatient
20%
Crohn Disease
18%
Diagnosis
18%
Patient with Ulcerative Colitis
15%
Ulcerative Colitis
15%
Confidence Interval
14%
Incidence
13%
Patient with Inflammatory Bowel Disease
13%
Patient with Crohn's Disease
11%
Meta Analysis
9%
Cohort Analysis
8%
Tumor Necrosis Factor
8%
Diseases
7%
Surgery
6%
Malignant Neoplasm
6%
Procedures
6%
Combination Therapy
5%
Non Insulin Dependent Diabetes Mellitus
5%
Hospital
5%
Uterine Cervix Cancer
5%
Hospitalization
5%
Prevalence
5%
Appendicitis
5%
Standardized Incidence Ratio
5%
Woman
5%
Eosinophilic Esophagitis
5%
Vedolizumab
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Crohn Disease
27%
Incidence
23%
Ulcerative Colitis
22%
Tumor Necrosis Factor
16%
Mercaptopurine
15%
Non Insulin Dependent Diabetes Mellitus
12%
Diseases
12%
Obesity
11%
Aminosalicylic Acid
9%
Necrosis
8%
Appendicitis
7%
Infection
7%
Malignant Neoplasm
6%
Antibiotics
6%
Infliximab
6%
Corticosteroid
5%
Uterine Cervix Cancer
5%
Microscopic Colitis
5%
Standardized Incidence Ratio
5%
Ileitis
5%
Eosinophilic Esophagitis
5%
Vedolizumab
5%